SCHEMBL10206604

SCHEMBL10206604

CC1(C)C(=O)Nc2cccc(CNc3nc(Nc4ccc(C5CCN(C6COC6)CC5)cc4)ncc3Cl)c21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 6/20 0.44
▸ STK17A Q9UEE5 1/20 0.43
▸ WEE1 P30291 2/20 0.42
▸ NTRK1 P04629 4/20 0.41
▸ STAT6 P42226 2/20 0.41
▸ FLT4 P35916 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ JAK3 P52333 2/20 0.40
▸ JAK2 O60674 2/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TTK P33981 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ ROS1 P08922 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ TYK2 P29597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14331595 0.86 STK17A (0.58) TNK2STK17AWEE1NTRK1FLT4
SCHEMBL10206633 0.86 EGFR (0.46) TNK2STK17AWEE1NTRK1STAT6
SCHEMBL10206199 0.85 STK17A (0.46) TNK2STK17AWEE1NTRK1STAT6
SCHEMBL10205122 0.85 STK17A (0.46) TNK2STK17AWEE1NTRK1STAT6
SCHEMBL14331681 0.85 STK17A (0.42) TNK2STK17AWEE1NTRK1STAT6
SCHEMBL10206622 0.85 ALK (0.44) TNK2STK17ASTAT6FLT4KDR
SCHEMBL10206626 0.85 STK17A (0.42) TNK2STK17AWEE1NTRK1STAT6
SCHEMBL10206600 0.84 FLT4 (0.44) TNK2STK17ANTRK1STAT6FLT4
SCHEMBL14331659 0.84 NTRK1 (0.44) TNK2STK17ANTRK1STAT6FLT4
SCHEMBL14331630 0.84 STK17A (0.42) TNK2STK17AWEE1NTRK1STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 TNK2 646/4885STK17A 3446/4885WEE1 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback